The use of Povidone-Iodine Nasal Spray and Mouthwash during the current Covid-19 Pandemic may protect healthcare workers and reduce cross infection.
Povidone-iodine (PVP-I) has a better anti-viral activity than other antiseptics, and has already been proven to be an effective virucide in vitro against severe acute respiratory syndrome and Middle East respiratory syndrome coronaviruses (SARS-CoV and MERS-CoV). Povidone iodine has been shown to be a safe therapy when inhaled nasally or gargled.
We propose that a protocolised nasal inhalation and oropharyngeal wash of PVP-I should be used in the current COVID-19 pandemic to limit the spread of SARS-CoV-2 from patients to healthcare workers (and vice versa) and thus reduce the incidence of COVID-19.
There should be regular use in patients with COVID-19 to limit upper respiratory SARS-CoV-2 contamination, but also use by healthcare workers prior to treating COVID 19 patients or performing procedures in and around the mouth/ nose during the pandemic, regardless of the COVID 19 status of the patient. Patients having such procedures should also be treated with PVP-I. The total iodine exposure proposed is within previously recorded safe limits in those without contraindications to its use.
Kirk-Bayley, Justin and Challacombe, Stephen and Sunkaraneni, Vishnu and Combes, James, The Use of Povidone Iodine Nasal Spray and Mouthwash During the Current Covid-19 Pandemic May Protect Healthcare Workers and Reduce Cross Infection. (March 28, 2020). Available at SSRN: https://ssrn.com/abstract=
Justin Kirk-Bayley Royal Surrey County Hospital
Stephen Challacombe King’s College London
San Sunkaraneni Royal Surrey County Hospital
James Combes Defence Medical Services
This research is currently under review by SSRN
 logo final copy.png)
- Pilot whole genome sequencing service - 22nd October 2024
- Coping with SAD: A guide for university students - 22nd October 2024
- Plugging into pain: ant toxin causes electrical sting - 18th October 2024
